BRPI0504220A - peptìdeos para discriminação de priÈnios - Google Patents

peptìdeos para discriminação de priÈnios

Info

Publication number
BRPI0504220A
BRPI0504220A BRPI0504220-8A BRPI0504220A BRPI0504220A BR PI0504220 A BRPI0504220 A BR PI0504220A BR PI0504220 A BRPI0504220 A BR PI0504220A BR PI0504220 A BRPI0504220 A BR PI0504220A
Authority
BR
Brazil
Prior art keywords
peptides
discrimination
prion
prionium
prize
Prior art date
Application number
BRPI0504220-8A
Other languages
English (en)
Inventor
Jian Zheng
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0504220A publication Critical patent/BRPI0504220A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"PEPTìDEOS PARA DISCRIMINAçãO DE PRIÈNIOS". A presente invenção proporciona peptídeos para a detecção de doenças causadas por priónio em seres humanos e animais. As composições e kits para a determinação da doença causada por priónio são também descritos.
BRPI0504220-8A 2004-09-30 2005-09-30 peptìdeos para discriminação de priÈnios BRPI0504220A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61453304P 2004-09-30 2004-09-30

Publications (1)

Publication Number Publication Date
BRPI0504220A true BRPI0504220A (pt) 2006-05-16

Family

ID=35432058

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0504220-8A BRPI0504220A (pt) 2004-09-30 2005-09-30 peptìdeos para discriminação de priÈnios

Country Status (13)

Country Link
EP (2) EP1643252B1 (pt)
JP (1) JP4837353B2 (pt)
KR (1) KR101355369B1 (pt)
CN (1) CN1804628B (pt)
AR (1) AR050965A1 (pt)
AT (2) ATE550666T1 (pt)
AU (1) AU2005209592B2 (pt)
BR (1) BRPI0504220A (pt)
CA (1) CA2518372C (pt)
DE (1) DE602005014597D1 (pt)
ES (2) ES2382935T3 (pt)
NZ (1) NZ542583A (pt)
PT (2) PT2085404E (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076497A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
EP1931695B1 (en) 2005-09-09 2013-04-10 Novartis AG Prion-specific peptoid reagents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806627A (en) 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
US5109464A (en) * 1991-05-24 1992-04-28 Amoco Corporation Rib waveguide optimized for low loss coupling to optical fibers and method of determining same
US20010001061A1 (en) 1997-02-21 2001-05-10 Prusiner Stanley B. Assay for disease related conformation of a protein
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
NZ516240A (en) 1999-06-23 2005-11-25 Caprion Pharmaceuticals Inc Prion protein peptides and uses thereof
US6261790B1 (en) 1999-07-15 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
WO2002000713A1 (en) 2000-06-26 2002-01-03 Universität Zürich Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen
EP1216258A1 (en) 1999-09-28 2002-06-26 Universität Zürich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
GB0014870D0 (en) * 2000-06-16 2000-08-09 King S College London Peptides
IL141950A0 (en) 2000-10-22 2002-03-10 Hadasit Med Res Service Diagnosis of prion diseases
WO2002057793A2 (en) 2001-01-19 2002-07-25 Baxter International Inc. Method of detecting prp protein and kits therefor
DE10107083C2 (de) * 2001-02-13 2003-02-20 Abdulgabar Salama Pentosan Polysulfat als Ligand zum Nachweis von Prionen
AU2003266801B2 (en) * 2002-12-19 2010-02-25 Ortho-Clinical Diagnostics, Inc Detection and diagnosis of transmissable spongiform encephalopathies

Also Published As

Publication number Publication date
AU2005209592A1 (en) 2006-04-13
ES2382935T3 (es) 2012-06-14
EP1643252B1 (en) 2009-05-27
HK1088066A1 (en) 2006-10-27
PT1643252E (pt) 2009-06-30
ATE550666T1 (de) 2012-04-15
EP1643252A3 (en) 2006-05-31
CN1804628B (zh) 2012-03-14
CN1804628A (zh) 2006-07-19
EP1643252A2 (en) 2006-04-05
EP2085404B1 (en) 2012-03-21
HK1137764A1 (en) 2010-08-06
KR20060051862A (ko) 2006-05-19
AU2005209592B2 (en) 2012-07-12
JP4837353B2 (ja) 2011-12-14
AR050965A1 (es) 2006-12-06
ATE432473T1 (de) 2009-06-15
ES2324919T3 (es) 2009-08-19
JP2006105988A (ja) 2006-04-20
CA2518372C (en) 2013-07-09
PT2085404E (pt) 2012-05-28
KR101355369B1 (ko) 2014-02-03
DE602005014597D1 (de) 2009-07-09
CA2518372A1 (en) 2006-03-30
EP2085404A1 (en) 2009-08-05
NZ542583A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
EP1723251A4 (en) IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
EP1572091A4 (en) COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
EP2191423A4 (en) FINANCIAL INFORMATION DELIVERY USING ADVERTISING SALES
EP1880222A4 (en) SYSTEM AND DEVICE FOR IDENTIFYING TISSUE SAMPLES
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
BR0112644A (pt) Método de identificar marcadores de câncer e usos destes no diagnóstico do câncer
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
EP1898899A4 (en) INHIBITORS OF THE FIBROBLAST ATTACHMENT PROTEIN ALPHA
EP1799242A4 (en) TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES
BRPI0606687A2 (pt) composições nutracêuticas
EP1919184A4 (en) CHARACTER AUTHENTICATION SYSTEM AND CHARACTER AUTHENTICATION PROCEDURE
FR2816411B1 (fr) Moyens de detection de la transformation pathologique de la proteine app et leurs applications
EP1846032A4 (en) LUCA2 AND THEREO BINDING ANTIBODIES
BRPI0504220A (pt) peptìdeos para discriminação de priÈnios
WO2012037232A3 (en) Compositions, methods and kits for detecting and treating alzheimer's disease
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.